Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab

Revvity and Lilly partner to accelerate AI drug discovery models

Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering

GSK secures European nod for easier-to-use Shingrix prefilled syringe

The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration

GSK reports breakthrough results in chronic hepatitis B trials

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data

Dr. Lal PathLabs launches tech-driven personalized wellness center 'Sovaaka'

Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks